Analytical Testing Partnership Program 2014 - 2015

Exhibit 10.19

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Testing. Advising. Assuring.

Analytical Testing Partnership Program 2014 - 2015

EXECUTIVE SUMMARY

Exova’s Health Sciences group has developed a strong relationship with intersectENT during the past decade. Over this period services provided have included method development, method and process validation, contaminant and unknown investigation, characterization of impurities, raw material and finished product testing and stability program services.

lntersectENT has had major success in product development, clinical efficacy and approval of its novel stent products. The company is experiencing rapid growth in moving from a purely research organization, to a manufacturing firm with a continuing R&D pipeline.

Exova has made investments to increase our capacity in tandem, so that intersectENT can continue to rely on Exova as the vendor of choice for analytical support and development. We appreciate your regular feedback and this has been very valuable in making changes and improvements so that our final product meets your expectations.

Exova is committed to working with intersectENT to manage costs during this period of rapid expansion, and to arrive at a mutually beneficial and cost effective long term partnership. In this light, for the next 24 months Exova is pleased to offer reduced prices for [*] services.

We are looking forward to continuing to support intersectENT for analytical testing development and stability needs.

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

PRICING PROPOSAL

Table 1. Custom Analyses

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Table 2. USP Monograph Testing

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

The pricing in the above tables is quoted for [*] day turnaround options. It is understood that [*].

TERMS AND CONDITIONS

This quotation is open for acceptance until December 15, 2013, and these prices will be in effect until December 31, 2015. It can be accepted on or before this date by signing and returning to Exova. After the validity date, Exova reserves the right to revise and/or withdraw the quotation as appropriate. This quotation has been prepared exclusively on behalf of Exova and is provided in confidence. The contents of this quotation including pricing Information is for the sole consideration of lntersectENT and cannot be divulged to a third party without the expressed written consent of Exova.

This quotation and the services are governed by the terms and conditions (“the Conditions”) as attached. This quotation may be accepted by signing the enclosed copy in the space provided below and returning it, for receipt by Exova within the time for acceptance given above. It will then constitute an agreement between us (the “Contract”). Please be advised that a purchase order is acceptable for billing purposes only, and the work is governed by the attached terms and conditions.

ACCEPTED BY

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.